Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Basit Öğe Kaydı
dc.authorid0000-0002-7846-0870
dc.authorid0000-0002-0156-5973
dc.contributor.authorHacıoğlu, Muhammet Bekir
dc.contributor.authorKöstek, Osman
dc.contributor.authorKarabulut, Senem
dc.contributor.authorTaştekin, Didem
dc.contributor.authorSezgin Göksu, Sema
dc.contributor.authorAlandağ, Celal
dc.contributor.authorAkagündüz, Baran
dc.contributor.authorBilgetekin, İrem
dc.contributor.authorCaner, Burcu
dc.contributor.authorŞahin, Ahmet Bilgehan
dc.contributor.authorYıldız, Birol
dc.contributor.authorKöse, Fatih
dc.date.accessioned2021-06-21T10:32:41Z
dc.date.available2021-06-21T10:32:41Z
dc.date.issued2020
dc.departmentTıp Fakültesi
dc.description*Sezgin Göksu, Sema ( Aksaray, Yazar )
dc.description.abstractPurpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the second- or third-line setting. Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a second- or third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included. Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (pPFS=0.22 and pOS=0.85). Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib.
dc.identifier.endpage1903en_US
dc.identifier.issn1107-0625
dc.identifier.issue4en_US
dc.identifier.scopusqualityN/A
dc.identifier.startpage1897en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12451/8126
dc.identifier.volume25en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherZerbinis Publications
dc.relation.ispartofJournal of B.U.ON.
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAnti-VEGFtherapy
dc.subjectChemotherapy
dc.subjectDisease Controlrate
dc.subjectHepatocellular Carcinoma
dc.subjectOverallsurvival
dc.subjectRegorafenib
dc.titleEfficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
dc.typeArticle

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu